Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 2/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4783789 | 0.83 | AXL (0.38) | CSNK2A1CNR2HTR2ACDK2 | |
| SCHEMBL4783385 | 0.74 | ALDH1A1 (0.54) | MAPTHPGDCSNK2A1CNR2 | |
| SCHEMBL4799096 | 0.71 | ALDH1A1 (0.46) | MAPTHPGDCSNK2A1CNR2 | |
| SCHEMBL4781802 | 0.71 | MAPT (0.50) | MAPTHPGDCNR2 | |
| SCHEMBL2466571 | 0.69 | MAPK1 (0.52) | MAPTHPGD | |
| SCHEMBL6152580 | 0.69 | MAPT (0.56) | MAPTHPGDCSNK2A1CNR2CDK2 | |
| SCHEMBL4785656 | 0.68 | LMNA (0.54) | MAPTHPGDCNR2 | |
| SCHEMBL4003944 | 0.66 | CDK2 (0.53) | MAPTHPGDCSNK2A1CNR2MCHR1 | |
| SCHEMBL22445861 | 0.65 | MAPT (0.47) | MAPTHPGDCSNK2A1CNR2MCHR1 | |
| SCHEMBL3370857 | 0.65 | MAPT (0.61) | MAPTHPGDCNR2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080153810-A1 | INDAZOLE DERIVATIVES USEFUL AS MELANIN CONCENTRATING RECEPTOR LIGANDS | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2008-06-26 | — | — | US | disclosed |
| WO-2008061109-A2 | INDAZOLE DERIVATIVES USEFUL AS MELANIN CONCENTRATING RECEPTOR LIGANDS | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2008-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153810-A1 | INDAZOLE DERIVATIVES USEFUL AS MELANIN CONCENTRATING RECEPTOR LIGANDS | MCHR1, MCHR2, MC1R | MAPT 1651/4885HPGD 730/4885CSNK2A1 1695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.